AGÕæÈ˹ٷ½

Trinity Industries (TRN) filed a Form 8-K dated 31 Jul 2025 to furnish, rather than file, its Q2-25 earnings materials. Exhibit 99.1 contains the news release with operating results for the quarter ended 30 Jun 2025; Exhibit 99.2 provides the prepared remarks of CEO E. Jean Savage, CFO Eric R. Marchetto, and the Investor Relations VP; Exhibit 99.3 is the investor slide deck. The company highlighted the use of multiple non-GAAP metrics—Adjusted EPS, Adjusted ROE, EBITDA, Adjusted EBITDA, and cash flow measures—and included GAAP reconciliations in the posted materials. Management did not supply quantitative data in the 8-K itself but reiterated that forward-looking non-GAAP reconciliations are impracticable due to variable items such as railcar mix, lease-portfolio sales and capital deployment. The disclosure is furnished under Items 2.02 and 7.01 and therefore is not deemed filed under the Exchange Act.

Form 4 insider activity � ClearPoint Neuro, Inc. (CLPT)

Chief Business Officer Jeremy L. Stigall purchased 1,608 shares of ClearPoint Neuro common stock on 06/30/2025 through the company’s Employee Stock Purchase Plan (ESPP). The acquisition price was $10.15, reflecting the ESPP’s 15 % discount to the lower of the market prices on the first or last day of the six-month purchase period (01/01/2025-06/30/2025). After the transaction, Stigall directly owns 72,355 CLPT shares.

No shares were sold and no derivative securities were involved. While the purchase is modest in size, insider buying—especially by a senior officer—tends to be interpreted as a sign of management’s confidence in the company’s prospects, albeit with limited immediate financial impact.

Form 4 insider activity � ClearPoint Neuro, Inc. (CLPT)

Chief Business Officer Jeremy L. Stigall purchased 1,608 shares of ClearPoint Neuro common stock on 06/30/2025 through the company’s Employee Stock Purchase Plan (ESPP). The acquisition price was $10.15, reflecting the ESPP’s 15 % discount to the lower of the market prices on the first or last day of the six-month purchase period (01/01/2025-06/30/2025). After the transaction, Stigall directly owns 72,355 CLPT shares.

No shares were sold and no derivative securities were involved. While the purchase is modest in size, insider buying—especially by a senior officer—tends to be interpreted as a sign of management’s confidence in the company’s prospects, albeit with limited immediate financial impact.

Form 4 insider activity � ClearPoint Neuro, Inc. (CLPT)

Chief Business Officer Jeremy L. Stigall purchased 1,608 shares of ClearPoint Neuro common stock on 06/30/2025 through the company’s Employee Stock Purchase Plan (ESPP). The acquisition price was $10.15, reflecting the ESPP’s 15 % discount to the lower of the market prices on the first or last day of the six-month purchase period (01/01/2025-06/30/2025). After the transaction, Stigall directly owns 72,355 CLPT shares.

No shares were sold and no derivative securities were involved. While the purchase is modest in size, insider buying—especially by a senior officer—tends to be interpreted as a sign of management’s confidence in the company’s prospects, albeit with limited immediate financial impact.

Match Group, Inc. (MTCH) â€� Form 4 insider transaction

Director Glenn H. Schiffman reported one transaction dated 30 June 2025 under the company’s 2020 Deferred Compensation Plan for Non-Employee Directors. The filing shows an acquisition of 486 share units of Match Group common stock at a reference price of $30.89 per unit. Following the credit, Mr. Schiffman’s aggregate beneficial ownership stands at 42,983 shares, comprising 37,933 directly-held shares and 5,050 deferred share units.

The transaction was coded “A� (acquisition) and executed automatically through the deferred compensation plan, not an open-market purchase. No derivative securities were reported. The ownership form is direct.

Given Match Group’s ~280 million shares outstanding, the incremental 486 units represent <0.0002% of total shares and are therefore immaterial to the company’s capital structure. However, continued share accumulation by a board member may be interpreted by some investors as a sign of ongoing alignment with shareholder interests.